KELUN PHARMA(SZ:002422) Xin Lang Cai Jing·2025-09-24 02:20Company Overview - Sichuan Kelun Pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on May 29, 2002, and listed on June 3, 2010. The company specializes in the development, production, and sales of large-volume parenteral solutions [1][2] - The main business revenue composition includes: non-infusion products 48.37%, infusion products 41.28%, R&D projects 7.01%, and others 3.33% [1] Financial Performance - For the first half of 2025, Kelun Pharmaceutical achieved operating revenue of 9.083 billion yuan, a year-on-year decrease of 23.20%. The net profit attributable to shareholders was 1.001 billion yuan, down 44.41% year-on-year [2] - Since its A-share listing, the company has distributed a total of 6.697 billion yuan in dividends, with 3.386 billion yuan distributed in the last three years [3] Stock Market Activity - On September 24, Kelun Pharmaceutical's stock price increased by 2.00%, reaching 37.69 yuan per share, with a trading volume of 1.05 billion yuan and a turnover rate of 0.22%. The total market capitalization is 60.231 billion yuan [1] - Year-to-date, the stock price has risen by 28.07%, with a 2.03% increase over the last five trading days, 2.14% over the last twenty days, and 6.14% over the last sixty days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on April 30, where the net buying amount was 31.8792 million yuan [1] Shareholder Structure - As of June 30, 2025, the number of shareholders is 34,200, an increase of 2.55% from the previous period. The average circulating shares per person decreased by 2.49% to 38,138 shares [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]